Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WST11 VTP in Localized Prostate Cancer
NCT00707356Phase 2Completed
- Sponsor
- Steba Biotech
- Start
- Sep 2008
- Primary completion
- Jan 2011
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of padeliporfin VTP in prostate cancer (PCa), sponsored by Steba Biotech. Primary endpoint: Negative biopsy in the treated lobe at 6 months. Started Sep 2008; status: completed.
02
Drugs
padeliporfin VTP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00707356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707356.